Halozyme Therapeutics, Inc. (HALO)
| Market Cap | 8.04B |
| Revenue (ttm) | 1.24B |
| Net Income (ttm) | 595.49M |
| Shares Out | 117.60M |
| EPS (ttm) | 4.74 |
| PE Ratio | 14.44 |
| Forward PE | 9.24 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,327,801 |
| Open | 68.30 |
| Previous Close | 68.30 |
| Day's Range | 67.40 - 70.50 |
| 52-Week Range | 42.01 - 79.50 |
| Beta | 0.96 |
| Analysts | Buy |
| Price Target | 74.91 (+9.53%) |
| Earnings Date | Nov 3, 2025 |
About HALO
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper... [Read more]
Financial Performance
In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $74.91, which is an increase of 9.53% from the latest price.
News
Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
SAN DIEGO , Nov. 6, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced the pricing of $650 million aggregate principal amount of 0% converti...
Halozyme Therapeutics, Inc. Announces Proposed Offering of $650 Million of Convertible Senior Notes due 2031 and $650 Million of Convertible Senior Notes due 2032
SAN DIEGO , Nov. 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), today announced that it intends to offer, subject to market conditions and other fact...
Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. ( HALO) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, ...
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
Royalty Revenue Increased 52% YOY to Record $236 million and Total Revenue Increased 22% YOY to Record $354 million Net Income Increased 28% YOY to $175 million; Adjusted EBITDA Increased 35% YOY to $...
Halozyme Just Bought Its Next Decade Of Growth
Halozyme's $750M Elektrofi acquisition expands its drug delivery leadership beyond ENHANZE into high-concentration biologic formulations. Elektrofi's Hypercon enables 400–500 mg/mL formulations for ≤2...
Halozyme to Report Third Quarter 2025 Financial and Operating Results
SAN DIEGO , Oct. 21, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2025 financial and operating results on Monday, Nove...
Strong And Rising: Halozyme Therapeutics Stock May Have More Upside
Halozyme Therapeutics (HALO) stock could be a solid choice to leverage the current momentum. Why? Because it offers strong margins, a low-debt capital structure, reasonable valuation, and strong momen...
Halozyme Therapeutics, Inc. (HALO) M&A Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) M&A Call October 1, 2025 8:30 AM EDT Company Participants Tram Bui - Head of Investor Relations & Corporate Communications Helen Torley - President, CEO & Di...
Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup
Halozyme Therapeutics said on Wednesday it will buy privately held Elektrofi for $750 million in cash, to expand its lineup with a technology that can deliver biologic medicines in small, concentrated...
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP ...
Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants Helen Torley - President, CEO & Director Conferenc...
Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT Company Participants Helen Torley - President, CEO & Director Conference Cal...
Identify Superstar Stocks Like Halozyme with Money Flows
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Inve...
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO...
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
Total Revenue Increased 41% YOY to $326 million and Royalty Revenue Increased 65% YOY to $206 million Net Income Increased 77% YOY to $165 million; Adjusted EBITDA Increased 65% YOY to $226 million; G...
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRNew...
Halozyme to Report Second Quarter 2025 Financial and Operating Results
SAN DIEGO , July 22, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and operating results on Tuesday, Au...
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)
Halozyme Therapeutics, Inc.'s ENHANZE technology drives strong near-term growth, but its key patent expires in 2027, raising long-term sustainability concerns. MDASE, once seen as the next growth engi...
Halozyme Therapeutics Added to Russell 1000® Index
SAN DIEGO , June 30, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that it has been added to the U.S. large-cap Russell 1000® Index, effective after market...
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
SC injection of VYVGART® is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional SAN DIEGO , June 20, 2025 /PRNewswire/ -- Halozyme Ther...
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) tod...
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
Halozyme Therapeutics reported strong Q1 2025 earnings with a 35% revenue increase, 54% net income growth, and raised full-year guidance, reinforcing its status as a top biotech growth story. Key grow...
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations & Corporate Communications Helen T...
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBIT...